Literature DB >> 24135406

Role of consolidation therapy in transplant eligible multiple myeloma patients.

Michele Cavo1, Annamaria Brioli, P Tacchetti, B A Zannetti, K Mancuso, E Zamagni.   

Abstract

The role of high-dose therapy and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM) has continued to evolve in recent years. The novel agents thalidomide, bortezomib, and lenalidomide have been successfully incorporated into induction therapy in preparation for ASCT and are currently being investigated also as post-ASCT consolidation and maintenance therapy. Consolidation treatment is generally short term and aims to increase the frequency and depth of response obtained with the previous treatment phases, including novel agent-based induction therapy and ASCT. This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24135406     DOI： 10.1053/j.seminoncol.2013.07.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  6 in total

1.  Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Authors:  Pieter Sonneveld; Emilie Asselbergs; Sonja Zweegman; Bronno van der Holt; Marie Jose Kersten; Edo Vellenga; Marinus van Marwijk-Kooy; Annemiek Broyl; Okke de Weerdt; Sarah Lonergan; Antonio Palumbo; Henk Lokhorst
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials.

Authors:  Minjie Gao; Guang Yang; Ying Han; Yuanyuan Kong; Huiqun Wu; Yi Tao; Fenghuang Zhan; Jumei Shi; Xiaosong Wu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials.

Authors:  Xiaoping Liu; Colin K He; Xiangyu Meng; Li He; Kaili Li; Qing Liang; Liang Shao; Shangqin Liu
Journal:  Onco Targets Ther       Date:  2015-06-15       Impact factor: 4.147

4.  Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.

Authors:  Annalisa Pezzi; Michele Cavo; Annibale Biggeri; Elena Zamagni; Oriana Nanni
Journal:  BMC Med Res Methodol       Date:  2016-11-09       Impact factor: 4.615

5.  Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Authors:  Ruth Wester; Bronno van der Holt; Emelie Asselbergs; Sonja Zweegman; Marie Jose Kersten; Edo Vellenga; Marinus van Marwijk Kooy; Okke de Weerdt; Monique Minnema; Sarah Lonergan; Antonio Palumbo; Henk Lokhorst; Annemiek Broijl; Pieter Sonneveld
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 6.  Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.

Authors:  Ho Sup Lee; Chang-Ki Min
Journal:  Korean J Intern Med       Date:  2016-09-01       Impact factor: 2.884
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.